Central Nervous System (CNS) Biomarkers: Technologies and Global Markets
Report Highlights
The global CNS biomarker market is projected to reach $5.1 billion by 2020 from $3.1 billion in 2015, at a compound annual growth rate (CAGR) of 10.4%.
Report Includes
- An overview of the global market for central nervous system (CNS) biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response.
- Analyses of global market trends, with data from 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2020.
- Evaluation of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
- Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others.
- Patent analyses.
- Profiles of major players in the field.
Report Scope
Current and projected product forecasts during the forecast period (2014 to 2020) are discussed. New products approved in 2013 and 2014 by the U.S. Food and Drug Administration (FDA), and those products expected to be approved within the forecast period are discussed. Figures for 2015 are estimated, except where actual results have been reported.
The report includes analysis of leading and emerging competitors in the current worldwide CNS biomarkers market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define the specific product strategies employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care. Detailed profiles are provided for current market leaders as well as companies with innovative products poised to advance within the forecast period.
Market figures are based on revenues at the manufacturers’ level and are projected at the 2015 dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products, and projected changes in the prevalence, diagnosis, and scripting rates for certain diseases.
Included in this report are forecasts by product, product category and company from 2015 through 2020. The study is arranged to offer an overview of the CNS biomarkers market accompanied by product, company, geography, and mechanism of action, with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data for each disease sub segment.
In general, excluded from this report are over-the-counter (OTC) medications, and other consumables that do not require a physician’s prescription.
Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented is on a global basis, unless specifically noted.
Frequently Asked Questions (FAQs)
Analyst Credentials
Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development. Jackson Highsmith is a pseudonym of the author.
Report Highlights
The global CNS biomarker market was estimated at $1.7 billion in 2011 and nearly $2 billion in 2012. The market is projected to reach $5.1 billion by the end of the forecast period of 2012 to 2017, representing a compound annual growth rate (CAGR) of 20.7%.
Report Includes
- An overview of the global market for central nervous system (CNS) biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response.
- Analyses of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017.
- Evaluations of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
- Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others.
- Patent analyses.
- Comprehensive company profiles of major players.
Report Highlights
-
The global CNS biomarker market was estimated at $1.3 billion in 2009 and is expected to reach close to $3.2 billion by 2015, with a compound annual growth rate (CAGR) of 17.1% from 2010 to 2015.
-
The CNS molecular diagnostic market will see the largest growth, with a compound annual growth rate (CAGR) of 172.3% from 2010 to 2015 due to the number of diagnostic tests that are in the pipeline. This sector is valued at $2 million in 2010 and is expected to be worth $302 million in 2015.
-
The growth rate for the CNS biomarker market for drug development will increase as more validated biomarkers become available for patient segmentation and assessment of efficacy for clinical trials. This sector is worth an estimated $162 million in 2010 and is expected to reach $355 million in 2015, a 17% compound annual growth rate (CAGR).